1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Delenex Therapeutics AG - Product Pipeline Review - 2016

Delenex Therapeutics AG - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 37 pages

Delenex Therapeutics AG - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Delenex Therapeutics AG - Product Pipeline Review - 2016’, provides an overview of the Delenex Therapeutics AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Delenex Therapeutics AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Delenex Therapeutics AG
- The report provides overview of Delenex Therapeutics AG including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Delenex Therapeutics AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Delenex Therapeutics AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Delenex Therapeutics AG’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Delenex Therapeutics AG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Delenex Therapeutics AG’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Delenex Therapeutics AG - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Delenex Therapeutics AG Snapshot 5
Delenex Therapeutics AG Overview 5
Key Information 5
Key Facts 5
Delenex Therapeutics AG - Research and Development Overview 6
Key Therapeutic Areas 6
Delenex Therapeutics AG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Delenex Therapeutics AG - Pipeline Products Glance 11
Delenex Therapeutics AG - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Delenex Therapeutics AG - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Delenex Therapeutics AG - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Delenex Therapeutics AG - Drug Profiles 16
DLX-1008 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
DLX-105 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
DLX-2323 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
DLX-2681 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
DLX-2751 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
DLX-2882 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
DLX-2907 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
DLX-2909 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
DLX-2201 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Monoclonal Antibody Conjugate for Oncology and Inflammation 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Monoclonal Antibody for Oncology and Inflammation 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Delenex Therapeutics AG - Pipeline Analysis 29
Delenex Therapeutics AG - Pipeline Products by Target 29
Delenex Therapeutics AG - Pipeline Products by Route of Administration 30
Delenex Therapeutics AG - Pipeline Products by Molecule Type 31
Delenex Therapeutics AG - Pipeline Products by Mechanism of Action 32
Delenex Therapeutics AG - Recent Pipeline Updates 33
Delenex Therapeutics AG - Dormant Projects 34
Delenex Therapeutics AG - Locations And Subsidiaries 35
Head Office 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37

List of Tables
Delenex Therapeutics AG, Key Information 5
Delenex Therapeutics AG, Key Facts 5
Delenex Therapeutics AG - Pipeline by Indication, 2016 7
Delenex Therapeutics AG - Pipeline by Stage of Development, 2016 9
Delenex Therapeutics AG - Monotherapy Products in Pipeline, 2016 10
Delenex Therapeutics AG - Phase III, 2016 11
Delenex Therapeutics AG - Phase II, 2016 12
Delenex Therapeutics AG - Phase I, 2016 13
Delenex Therapeutics AG - Preclinical, 2016 14
Delenex Therapeutics AG - Discovery, 2016 15
Delenex Therapeutics AG - Pipeline by Target, 2016 29
Delenex Therapeutics AG - Pipeline by Route of Administration, 2016 30
Delenex Therapeutics AG - Pipeline by Molecule Type, 2016 31
Delenex Therapeutics AG - Pipeline Products by Mechanism of Action, 2016 32
Delenex Therapeutics AG - Recent Pipeline Updates, 2016 33
Delenex Therapeutics AG - Dormant Developmental Projects,2016 34

List of Figures
Delenex Therapeutics AG - Pipeline by Top 10 Indication, 2016 7
Delenex Therapeutics AG - Pipeline by Stage of Development, 2016 9
Delenex Therapeutics AG - Monotherapy Products in Pipeline, 2016 10
Delenex Therapeutics AG - Pipeline by Target, 2016 29
Delenex Therapeutics AG - Pipeline by Route of Administration, 2016 30
Delenex Therapeutics AG - Pipeline by Molecule Type, 2016 31
Delenex Therapeutics AG - Pipeline Products by Mechanism of Action, 2016 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.